<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03410953</url>
  </required_header>
  <id_info>
    <org_study_id>IBS-VACANTIB-1701</org_study_id>
    <secondary_id>2016-004991-23</secondary_id>
    <secondary_id>GRS1360/A/16</secondary_id>
    <secondary_id>17/1311</secondary_id>
    <nct_id>NCT03410953</nct_id>
  </id_info>
  <brief_title>Vaccination Adjuved Against Hepatitis B in SACYL Workers Typed as no Responders to Conventional Vaccines</brief_title>
  <official_title>Vaccination Adjuved Against Hepatitis B in SACYL Workers Typed as no Responders to Conventional Vaccines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IBSAL-Instituto de Investigación Biomédica de Salamanca, Fundación IECSCYL-IBSAL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Health workers with biological risk in their tasks, who have been vaccinated as
      non-responders to conventional vaccination against Hepatitis B. To provide Health
      workers-staff with an additional protection tool against hepatitis B infection. To evaluate
      the efficacy of the adjuvanted vaccine in healthy nonresponders to conventional hepatitis B
      vaccine
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 13, 2018</start_date>
  <completion_date type="Anticipated">January 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>non-responders to conventional treatment of hepatitis B vaccination and consent to participate</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Protective levels of antibodies after treatment</measure>
    <time_frame>Between 40 and 60 days after the last dose given</time_frame>
    <description>Measurement of antibody antiHBs: before the first dose and a month after the administration of each dose. Collection of adverse effects during administration and all those that could be related to the vaccine and that occur within 30 days after each dose</description>
  </primary_outcome>
  <enrollment type="Anticipated">47</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Hepatitis</condition>
  <condition>Hepatitis, Viral, Human</condition>
  <condition>Hepatitis B Immunization</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fendrix suspension for injection Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed).</intervention_name>
    <description>The primary immunisation consists of 4 separate 0.5 ml doses administered at the following schedule:
1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Health workers in the Health Area of Salamanca, Zamora, Leon, Valladolid and Palencia.

          -  Criteria defining them as NO responders to the conventional hepatitis B vaccine: anti
             HBsAb titers &lt;10 mIU / ml following the application of six doses of conventional
             vaccine at 20 μg doses (two complete guidelines).

        Exclusion Criteria:

          -  Known allergy to the active substance or any of the other ingredients of the medicinal
             product (included in section 6 of the product data sheet).

          -  Subjects that have ever had an allergic reaction to any vaccine against hepatitis B.

          -  Subjects have a serious infection with fever.

          -  Subjects for whom informed consent is not obtained.

          -  Subjects that have not revoked the consent initially signed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose L. Bravo-Grande, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IBSAL-Instituto de Investigación Biomédica de Salamanca</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jose L. Bravo-Grande, MD PhD</last_name>
    <phone>+34 923291100</phone>
    <phone_ext>55587</phone_ext>
    <email>jlbravo@saludcastillayleon.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carmen Arias, PhD</last_name>
    <phone>+34 923210960</phone>
    <email>ensayosclinicos@ibsal.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de León</name>
      <address>
        <city>León</city>
        <zip>24080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose-Manuel delaTorre-Robles, MD</last_name>
      <phone>+34 987 237400</phone>
      <email>torrer@saludcastillayleon.es</email>
    </contact>
    <investigator>
      <last_name>Jose-Manuel de-la-Torre-Robles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de Palencia</name>
      <address>
        <city>Palencia</city>
        <zip>34005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Hervella-Ordoñez, MD</last_name>
      <phone>979167000</phone>
      <email>mhervella@saludcastillayleon.es</email>
    </contact>
    <investigator>
      <last_name>Marina Hervella-Ordoñez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose L. Bravo-Grande, MD PhD</last_name>
      <phone>+34 923291100</phone>
      <phone_ext>55587</phone_ext>
      <email>jlbravo@saludcastillayleon.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Rescalvo-Santiago, MD</last_name>
      <phone>+34 983420400</phone>
      <phone_ext>86602</phone_ext>
      <email>frescalvo@saludcastillayleon.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial de Zamora</name>
      <address>
        <city>Zamora</city>
        <zip>49022</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose-Manuel delaFuente-Martín, MD</last_name>
      <phone>+34 980548300</phone>
      <email>jmfuente@saludcastillayleon.es</email>
    </contact>
    <investigator>
      <last_name>Jose-Manuel delaFuente-Martín, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2018</study_first_submitted>
  <study_first_submitted_qc>January 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2018</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis, Viral, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

